Aim To synthesize novel sulfonohydrazide derivatives and evaluate their physicochemical and enzyme‑inhibitory profiles, together with the corresponding structure–activity relationships.Methods A series of six hydrazide derivatives (NLs1–NLs6) was synthesized and subjected to comprehensive in vitro enzymatic evaluation against four critical targets: 15-Lipoxygenase (15-LOX), Carbonic anhydrase II (β-CA-II), Butyrylcholinesterase (BChE), and Acetylcholinesterase (AChE). Furthermore, to determine the stability and binding of the synthesized compounds, molecular dynamic simulations and molecular docking were performed.Results Bromo- and fluoro-substituted NLs2 (IC50 = 0.29 ± 0.02 µM) and NLs3 (IC50 = 0.54 ± 0.01 µM) showed significant activity against AChE. Furthermore, compound NLs4 demonstrated significant cholinesterase inhibitory activities, i.e. AChE and BChE, although the inhibitory potential against AChE (IC50 = 0.72 ± 0.11 µM) was comparatively higher than that of BChE (IC50 = 0.65 ± 0.03 µM). MD trajectories of all three systems involving proteins and NLs3 indicate that AChE-NLs3 exhibit the highest level of overall structural stability, closely followed by LOX-NLs3 as both have a low RMSD amplitude and low residue variations.Conclusion These findings identify several derivatives as promising multi-target lead compounds for the treatment of diseases driven by the dysregulation of lipid metabolism, cholinergic signaling, and carbonic anhydrase activity.
No takes yet. Share an insight, caveat, or question.
Karim et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: